<DOC>
	<DOCNO>NCT01958021</DOCNO>
	<brief_summary>This multi-center , randomize , double-blinded , placebo control trial .</brief_summary>
	<brief_title>Study Efficacy Safety LEE011 Postmenopausal Women With Advanced Breast Cancer . ( MONALEESA-2 )</brief_title>
	<detailed_description>The purpose study assess efficacy LEE011 , measure progression free survival ( PFS ) , postmenopausal woman HR positive , HER2 negative advance breast cancer receive prior treatment advance disease .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>1 . Women advance ( locoregionally recurrent metastatic ) breast cancer amenable curative therapy . 2 . Patient postmenopausal . Postmenopausal status define either : Prior bilateral oophorectomy Age ≥60 Age &lt; 60 amenorrhea 12 month ( absence chemotherapy , tamoxifen , toremifen , ovarian suppression ) FSH estradiol postmenopausal range per local normal range Note : For woman therapyinduced amenorrhea , serial measurement FSH and/or estradiol need ensure postmenopausal status . Ovarian radiation treatment luteinizing hormonereleasing hormone agonist ( LHRHa ) ( goserelin acetate leuprolide acetate ) permit induction ovarian suppression trial . 3 . No prior systemic anticancer therapy advance disease . 4 . Patient histologically and/or cytologically confirm diagnosis estrogenreceptor positive and/or progesterone receptor positive breast cancer local laboratory . 5 . Patient HER2negative breast cancer define negative situ hybridization test IHC status 0 , 1+ 2+ . If IHC 2+ , negative situ hybridization ( FISH , CISH , SISH ) test require local laboratory test . 6 . Patient must either : • Measurable disease , i.e. , least one measurable lesion per RECIST 1.1 criterion ( Tumor lesions previously irradiate subjected locoregional therapy consider measurable disease progression treat site completion therapy clearly document ) . OR • If measurable disease present , least one predominantly lytic bone lesion must present ( Patients measurable disease one predominantly lytic bone lesion previously irradiate eligible documented evidence disease progression bone lesion irradiation ) . 7 . Patient Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 1 . Patient receive CDK4/6 inhibitor . 2 . Patient receive prior systemic anticancer therapy ( include hormonal therapy chemotherapy ) advance breast cancer Note : Patients receive ( neo ) adjuvant therapy breast cancer eligible . If prior neo ( adjuvant ) therapy include letrozole anastrozole disease free interval must great 12 month completion treatment randomization . Patients receive ≤ 14 day letrozole anastrozole advanced disease prior randomization eligible . Any prior ( neo ) adjuvant anticancer therapy must stop least 5 halflives 7 day , whichever longer , randomization 3 . Patient concurrently use anticancer therapy . 4 . Patient concurrent malignancy malignancy within 3 year randomization , exception adequately treat , basal squamous cell carcinoma , nonmelanomatous skin cancer curatively resect cervical cancer . 5 . Patient active cardiac disease history cardiac dysfunction include follow : History angina pectoris , symptomatic pericarditis , myocardial infarction within 12 month prior study entry History document congestive heart failure ( New York Heart Association functional classification IIIIV ) Documented cardiomyopathy Patient Left Ventricular Ejection Fraction ( LVEF ) &lt; 50 % determined Multiple Gated acquisition ( MUGA ) scan echocardiogram ( ECHO ) History cardiac arrhythmia , e.g. , ventricular , supraventricular , nodal arrhythmia , conduction abnormality previous 12 month . On screening , follow cardiac parameter : bradycardia ( heart rate &lt; 50 rest ) , tachycardia ( heart rate &gt; 90 rest ) , PR interval &gt; 220 msec , QRS interval &gt; 109 msec , QTcF &gt; 450 msec . Systolic blood pressure &gt; 160 &lt; 90 mmHg 6 . Patient currently receive follow medication discontinue 7 day prior start treatment : That know strong inducer inhibitor CYP3A4 . That know risk prolong QT interval induce Torsades de Pointes . That narrow therapeutic window predominantly metabolize CYP3A4 . Herbal preparations/medications</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>HR-positive</keyword>
	<keyword>HER2-negative</keyword>
	<keyword>Advanced breast cancer</keyword>
	<keyword>LEE011</keyword>
	<keyword>Letrozole</keyword>
	<keyword>CDK</keyword>
	<keyword>CDK4</keyword>
	<keyword>CDK6</keyword>
	<keyword>CDK4/6</keyword>
	<keyword>Phase III</keyword>
	<keyword>ER-positive</keyword>
	<keyword>PR-positive</keyword>
	<keyword>Postmenopausal</keyword>
</DOC>